RECRUITINGINTERVENTIONAL
Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders
About This Trial
Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.
Who May Be Eligible (Plain English)
Who May Qualify:
\- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair
Who Should NOT Join This Trial:
- Use of anti-resorptive medication
- Confounding illnesses
- Pregnancy
- Allergy towards the components given on the test days
- Hgb\<6.5 mmol/L
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
\- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair
Exclusion Criteria:
* Use of anti-resorptive medication
* Confounding illnesses
* Pregnancy
* Allergy towards the components given on the test days
* Hgb\<6.5 mmol/L
Treatments Being Tested
OTHER
Meal test
Ingestion of an oral liquid meal (nutridrink), 3.3 mL/kg body weight.
OTHER
GIP + GLP-2
Subcutaneous GIP + GLP-2 injection (1 mL containing 100 microgram GIP + 1 mL containing 400 microgram GLP-2).
OTHER
Placebo
Subcutaneous saline injection (2 mL isotonic saline).
Locations (1)
Rigshospitalet
Copenhagen, Denmark